Related Experiment Video
Updated: Feb 4, 2026

Administration of Volatile Anesthetics to Zebrafish Larvae for Behavioral Observation
Published on: June 6, 2025
Volatile anesthetics sevoflurane targets leukemia stem/progenitor cells via Wnt/β-catenin inhibition
Xuguang Ruan1, Weihang Jiang1, Pingrui Cheng1
1Department of Anesthesiology, Panyu Central Hospital, Guangzhou, China.
Abstract:
Most of the studies regarding the direct effect of anesthetics on tumour cells are focused on opioids and voltage-gated sodium channels. Little is known on the effect of volatile anesthetics on tumour progression. In this study, we show that sevoflurane, a volatile anesthetic, negatively affects chronic myeloid leukemia (CML) CD34 stem/progenitor cells' biological properties. Sevoflurane significantly inhibits the growth of a panel of CML cell lines in a dose-dependent manner without affecting their survival. It also inhibits proliferation, differentiation and self-renewal capacities but not survival of CML CD34 cells. In addition, sevoflurane significantly augments dasatinib's efficacy in CML cell lines and stem/progenitors. Mechanistically, sevoflurane dose-dependently decreases levels of β-catenin and c-Myc but not phospho-P38 MAPK in K562 and CML CD34 cells. The decreased Wnt/ β-catenin activity and the reduced levels of Wnt/β-catenin-targeted transcriptions are observed in CML cells exposed to sevoflurane. The complete rescue of the inhibitory effects of sevoflurane in K562 and CML CD34 cells by β-catenin stabilization using both genetic and pharmacological approaches further demonstrates that sevoflurane acts on CML cells via a β-catenin-dependent manner. Our results clearly show the direct and negative effects of sevoflurane on the leukemia cell lines as well as leukemia stem/progenitors. Our findings also reveal Wnt/β-catenin as the target of volatile anesthetics.
Insights
Sevoflurane, a volatile anesthetic, inhibits chronic myeloid leukemia (CML) cell growth and stem cell properties. It enhances dasatinib efficacy by targeting the Wnt/β-catenin pathway.
Area of Science:
- Oncology
- Anesthesiology
- Molecular Biology
Background:
- Limited research exists on volatile anesthetics' impact on tumor progression.
- Opioids and sodium channels are the primary focus regarding anesthetics and tumor cells.
Purpose of the Study:
- To investigate the direct effects of sevoflurane on chronic myeloid leukemia (CML) cells.
- To elucidate the mechanisms underlying sevoflurane's action on CML stem/progenitor cells.
Main Methods:
- Dose-dependent assays on CML cell lines and CD34+ stem/progenitor cells.
- Analysis of cell proliferation, differentiation, self-renewal, and survival.
- Western blotting for key signaling molecules (β-catenin, c-Myc, phospho-P38 MAPK).
- Assessment of Wnt/β-catenin pathway activity and targeted gene expression.
- Rescue experiments using genetic and pharmacological β-catenin stabilization.
Main Results:
- Sevoflurane inhibited CML cell line growth and CML CD34+ stem/progenitor cell proliferation, differentiation, and self-renewal without affecting survival.
- Sevoflurane significantly enhanced the efficacy of dasatinib in CML cells.
- Mechanistically, sevoflurane decreased β-catenin and c-Myc levels, reducing Wnt/β-catenin pathway activity.
- Stabilization of β-catenin rescued the inhibitory effects of sevoflurane, confirming a β-catenin-dependent mechanism.
Conclusions:
- Sevoflurane exerts direct, negative effects on leukemia cell lines and stem/progenitor cells.
- The Wnt/β-catenin pathway is identified as a key target for sevoflurane's action in CML.
- Findings suggest potential therapeutic implications for sevoflurane in CML treatment, particularly in combination with targeted therapies.
More Related Videos
Related Concept Videos
Catenins
Catenins in Cell Junctions
Catenins bind to cell adhesion molecules such as cadherins and link them to different cytoskeletal proteins depending on the type of cell junction. At the...
Volatilization
Feedback Inhibition
Adult Stem Cells
Embryonic Stem Cells
Canonical Wnt Signaling Pathway

